Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2 + ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response .